{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:50:04Z","timestamp":1791910204855,"version":"4.3.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We conducted a retrospective review to characterize adverse events in patients receiving oral linezolid, trimethoprim-sulfamethoxazole, voriconazole, and itraconazole monitored under an outpatient parenteral antimicrobial therapy program. Among 118 patients, 61% incurred at least 1 adverse event during treatment, highlighting the need for evidence-based monitoring protocols for complex outpatient antimicrobial therapy.<\/jats:p>","DOI":"10.1093\/ofid\/ofag590","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:34:58Z","timestamp":1789673698000},"source":"Crossref","is-referenced-by-count":0,"title":["High Rate of Adverse Events in Patients Receiving Oral Antimicrobials Under a COpAT Monitoring Protocol"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7323-330X","authenticated-orcid":false,"given":"Ciara","family":"Sawey","sequence":"first","affiliation":[{"name":"Department of Molecular, Cellular, and Developmental Biology, University of California , Santa Barbara, California ,","place":["USA"]},{"name":"Division of Infectious Diseases, University of Rochester , Rochester, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6916-3903","authenticated-orcid":false,"given":"Colleen","family":"Burgoyne","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Rochester , Rochester, New York ,","place":["USA"]},{"name":"State University of New York \u2013 Brockport, School of Nursing , Brockport, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3719-116X","authenticated-orcid":false,"given":"Angelina","family":"Winbush","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester , Rochester, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-2593","authenticated-orcid":false,"given":"Brandon W","family":"Qualls","sequence":"additional","affiliation":[{"name":"Clinical Nursing Research Center, University of Rochester Medicine , Rochester, New York ,","place":["USA"]},{"name":"University of Rochester School of Nursing & Health Sciences , Rochester, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-9163","authenticated-orcid":false,"given":"Sonal","family":"Munsiff","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Rochester , Rochester, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2558-1027","authenticated-orcid":false,"given":"Alexandra","family":"Yamshchikov","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Rochester , Rochester, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2026101312114938200_ofag590-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026101312114938200_ofag590-B2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101312114938200_ofag590-B3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101312114938200_ofag590-B4","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1017\/ash.2022.40","article-title":"Survey of pharmacists on their roles and perceptions of outpatient parenteral antimicrobial therapy in the United States","volume":"2","author":"Rivera","year":"2022","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2026101312114938200_ofag590-B5","doi-asserted-by":"crossref","first-page":"ofae683","DOI":"10.1093\/ofid\/ofae683","article-title":"Implementing oral antibiotics for bone and joint infections: lessons learned and opportunities for improvement","volume":"11","author":"Hawkins","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026101312114938200_ofag590-B6","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/jac\/dkz122","article-title":"From \u2018OPAT\u2019 to \u2018COpAT': implications of the OVIVA study for ambulatory management of bone and joint infection","volume":"74","author":"Seaton","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026101312114938200_ofag590-B7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jac\/dkt303","article-title":"Association of laboratory test result availability and rehospitalizations in an outpatient parenteral antimicrobial therapy programme","volume":"69","author":"Huck","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026101312114938200_ofag590-B8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/antibiotics12020330","article-title":"Usefulness of routine laboratory tests for follow-up of patients receiving outpatient parenteral antimicrobial therapy run by infectious diseases fellows","volume":"12","author":"Frisby","year":"2023","journal-title":"Antibiotics"},{"key":"2026101312114938200_ofag590-B9","doi-asserted-by":"crossref","first-page":"e00579","DOI":"10.1128\/aac.00579-22","article-title":"Why bother? Lab monitoring in beta-lactam outpatient parenteral antimicrobial therapy","volume":"66","author":"Zukauckas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101312114938200_ofag590-B10","doi-asserted-by":"crossref","first-page":"ofae005","DOI":"10.1093\/ofid\/ofae005","article-title":"Making the EHR work for you\u2014modifications of an electronic health record system to improve tracking and management of patients receiving outpatient parenteral antibiotic therapy","volume":"11","author":"Munsiff","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026101312114938200_ofag590-B11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/DHPS.S6321","article-title":"Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections","volume":"2","author":"Neofytos","year":"2010","journal-title":"Drug Healthc Patient Saf"},{"key":"2026101312114938200_ofag590-B12"},{"key":"2026101312114938200_ofag590-B13","volume-title":"Mandell, Douglas, and Bennett's principles and practice of infectious diseases","author":"Bennett","year":"2019","edition":"9th ed"},{"key":"2026101312114938200_ofag590-B14","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026101312114938200_ofag590-B15","first-page":"20499361231192771","article-title":"Taking the route less traveled: on the way to COpAT","volume":"10","author":"Pertzborn","year":"2023","journal-title":"Ther Adv Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag590\/71227511\/ofag590.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag590\/71227511\/ofag590.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag590\/71227511\/ofag590.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:11:57Z","timestamp":1791907917000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag590\/8817488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag590","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,19]]},"article-number":"ofag590"}}